WebASCO’s growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe. WebLisa A. Carey, MD, ScM, FASCO University of North Carolina at Chapel Hill Chapel Hill, NC Charles M. Perou, PhD University of North Carolina at Chapel Hill Chapel Hill, NC Eric P. Winer, MD Dana-Farber Cancer Institute Boston, MA Kornelia Polyak, MD, PhD Dana-Farber Cancer Institute Boston, MA 4:00-6:00 Educational Sessions

Our Researchers - Play for P.I.N.K.

WebASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial aiming to describe the performance of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer with a potentially actionable genomic variant. Visit Site WebIn response to member needs, I’m excited to announce that our U.S. members now have access to SafeHaven, a comprehensive collection of physician well-being resources. hondenschool fun for 2

Rachna Shroff, MD, FASCO (@rachnatshroff) / Twitter

WebOct 18, 2012 · Meet Rachna Shroff, MD, interim chief of hematology/oncology, whose roots here are deep. “My mother was a woman physician of color in the 1980s & an incredibly well-respected physician in Tucson. WebLed by Eric P. Winer, MD, Dana-Farber Brigham Cancer Center breast oncology specialists joined OncLive® for a discussion focusing on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. Topics included: Risk of patients with breast cancer for developing COVID-19 hondenpension a1